Format

Send to:

Choose Destination
See comment in PubMed Commons below
Reprod Toxicol. 2014 Dec;50:134-7. doi: 10.1016/j.reprotox.2014.10.017. Epub 2014 Oct 31.

Use of ondansetron during pregnancy and congenital malformations in the infant.

Author information

  • 1National Board of Health and Welfare, Stockholm, Sweden. Electronic address: bengt.danielsson@socialstyrelsen.se.
  • 2National Board of Health and Welfare, Stockholm, Sweden.
  • 3Tornblad Institute, Lund University, Lund, Sweden.

Abstract

The study investigates teratogenic risks with ondansetron (Zofran(®)). Data from the Swedish Medical Birth Register combined with the Swedish Register of Prescribed Drugs were used to identify 1349 infants born of women who had taken ondansetron in early pregnancy, 1998-2012. Presence of congenital malformations in the offspring was identified with three national health registers. In a Mantel-Haenszel analysis adjustment was made for year of delivery, maternal age, parity, smoking in early pregnancy and pre-pregnancy body mass index. Risks were expressed as odds or risk ratios with 95% confidence intervals. No statistically significantly increased risk for a major malformation was found. The risks for a cardiovascular defect and notably a cardiac septum defect were increased and statistically significant (OR=1.62, 95% CI 1.04-2.14, and RR 2.05, 95% CI 1.19-3.28, respective). The teratogenic risk with ondansetron is low but an increased risk for a cardiac septum defect is likely.

Copyright © 2014 Elsevier Inc. All rights reserved.

KEYWORDS:

Antiemetics; Cardiovascular defects; Congenital malformations; Meclozine; Nausea and vomiting in pregnancy; Ondansetron

PMID:
25450422
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk